Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Current Deferred Revenue (2020 - 2024)

Allogene Therapeutics' Current Deferred Revenue history spans 5 years, with the latest figure at $86000.0 for Q1 2024.

  • For Q1 2024, Current Deferred Revenue changed 0.0% year-over-year to $86000.0; the TTM value through Mar 2024 reached $86000.0, changed 0.0%, while the annual FY2023 figure was $86000.0, 90.28% down from the prior year.
  • Current Deferred Revenue for Q1 2024 was $86000.0 at Allogene Therapeutics, roughly flat from $86000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $39.0 million in Q4 2020 and bottomed at $86000.0 in Q1 2023.
  • The 5-year median for Current Deferred Revenue is $272000.0 (2021), against an average of $3.1 million.
  • The largest annual shift saw Current Deferred Revenue crashed 99.6% in 2021 before it soared 467.31% in 2022.
  • A 5-year view of Current Deferred Revenue shows it stood at $39.0 million in 2020, then tumbled by 99.6% to $156000.0 in 2021, then skyrocketed by 467.31% to $885000.0 in 2022, then crashed by 90.28% to $86000.0 in 2023, then changed by 0.0% to $86000.0 in 2024.
  • Per Business Quant, the three most recent readings for ALLO's Current Deferred Revenue are $86000.0 (Q1 2024), $86000.0 (Q4 2023), and $236000.0 (Q3 2023).